Original Article
Serum levels of IL-6 and IL-17 in multiple sclerosis, neuromyelitis optica patients and healthy subjects

Fereshte Ashtari¹,², Reyhanehsadat Madanian¹,², Vahid Shaygannejad¹,², Sayyed Hamid Zarkesh³, Keyvan Ghadimi⁴

¹Isfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran; Departments of ²Neurology, ³Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran; ⁴School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Received September 27, 2019; Accepted December 2, 2019; Epub December 15, 2019; Published December 30, 2019

Abstract: Background: Studies reported that evaluating the interleukin serum level of MS and NMO patients is helpful for differentiating these two diseases from each other. This study aimed to compare the level of IL-6 and IL-17 in MS and NMO patients in comparison to controls in patients who referred to Kashani hospital clinics. The level of serum IL-6 and IL-17 were measured by ELISA test in all patients. Participants were divided in to three groups include MS patients, NMO patients and controls and the level of IL-6 and IL-17 were compared in this three groups. Results: Mean of serum level of IL-6 in the NMO group was significantly lower than MS and healthy subject (P=0.02 for NMO and MS, P=0.001 for NMO and healthy subjects) but there was no significant difference between MS and healthy subjects (P=0.09). The mean of serum level of IL-17 in the NMO group was significantly higher than MS and healthy subject (P<0.001 for both). Also the mean of serum level of IL-17 in the MS was significantly higher than NMO (P=0.01). A positive significant correlation between age and serum level of IL-6 in all subjects (r=0.23, P=0.01). There was a positive significant correlation between age and serum level of IL-17 in MS and NMO patients (r=0.28, P=0.012). Conclusion: Using IL-17 and IL-6 were inflammatory markers to diagnosis of NMO, MS and healthy subjects.

Keywords: Multiple sclerosis, neuromyelitis optica (NMO), interleukin

Introduction

Multiple sclerosis [1] is the most common inflammatory demyelinated central nervous system (CNS) disease and the third common disease that causes major disability [2]. There are evidences that the main mechanism of these diseases is autoimmune inflammatory reaction mediated by some components of immune system [3-6]. MS is more popular in young women and the prevalence in different countries is between 30-190 per 100,000 [7]. Neuromyelitis optica (NMO) is another inflammatory CNS disorder with presentation of optic neuritis and myelitis that resemble those of MS [8-10].

Although NMOSD is different from MS regarding to neuroimaging, pathological and immunological features, sometimes make correct initial diagnosis is difficult due to similarities of presentations [11].

However, early diagnosis and appropriate treatment with immunosuppressive drugs is in paramount of importance in order to prevent severe disability in NMOSD patients. Furthermore, it should be noticed that some commonly medical therapy used in MS such as olimod, interferons and natalizumab may result aggressive disease activity in NMOSD. As a result, early differentiation between NMOSD and MS has become increasingly important [12, 13].

Whereas serum autoantibody NMO-IgG is known as a specific biomarker for NMOSD diagnosis with high sensitivity and specificity, many of NMOSD patients are seronegative [14, 15]. Though considering other biomarkers for distinguish between NMOSD and MS patients...
particularly when neuroimaging findings are not characteristic seems reasonable [15].

Although the immunological differences between MS and NMO have recognized by several studies, a clear definition remains controversial [15].

Over last decades, several studies have been done to illustrate the serum or cerebrospinal fluid (CSF) cytokines and chemokines profiles among patients with NMOSD and MS. Matsushita was suggested over expression of a cluster of Th-17 and Th-1 related proinflammatory cytokines in NMO rather than MS [16]. There are some more studies supporting the idea that increased level of Th-17 and Th-2 related molecules especially IL-6 may be essential factors for developing NMO [17-20]. Furthermore, biomarkers as CSF glial fibrillary acidic protein (GFAP) are related to clinical severity of NMO relapse [21].

According to these studies, there is a probable correlation between the CSF or serum concentration of IL-6 and IL-17 in the pathogenesis of NMOSD [17-22].

Therefore, evaluation of these biomarkers may be useful to differentiate between these two demyelinating disorders and it might make a contribution to potential therapeutic targeting program in the future. This study was done to compare the serum levels of IL-6 and IL-17 in acute relapse phase of MS, NMOSD and healthy subjects in order to find any difference for the early differentiation of these diseases.

Methods

Study design

This study is a case control study that evaluated the serum level of IL-6 and IL-17 in MS and NMO patients in comparison to controls in patients who referred to Kashani hospital clinics in Isfahan University of Medical Science (IUMS) and neurologist office cooperates in this study in 2016-2017. Inclusion criteria were as followed: 1) age more than 18, 2) presence of primary symptoms of MS or NMO, 3) receiving no corticosteroid at least in recent one month and 4) patient’s willingness to participate in this study. Exclusion criteria were as followed: 1) having underlying disease includes diabetes, vasculitis, inflammation and rheumatologic diseases and 2) patient’s unwillingness to continue this study. This study was approved by IUMS Ethical Committee.

About 101 patients with MS or NMO were selected based on inclusion and exclusion criteria. Patients were divided in to NMO or MS group based on their clinical manifestations and then followed for one year to approve this diagnosis. Also 39 healthy individuals were selected from patients who referred to neurology clinic because of other complaints that had no history of underlying disease and were homogenous in age and gender as a control group. At first demographic data includes age and gender were collected by introducing patients. Then, blood sampling was done for each participant from peripheral vein (7 cc) and then kept in laboratory in standard situation. At the time of analysis, the serum of these blood samples, were separated. Then, the level of serum IL-6 and IL-17 were measured by ELISA test (Boster Biological Thechnology Co., Ltd., Wuhan, China). All patients were followed for certain diagnosis of MS or NMO and the proper diagnosis of MS or NMO were registered for patients. Finally, participants were divided in to three groups include MS patients, NMO patients and controls and the level of IL-6 and IL-17 were compared in this three groups.

Three groups were matched in the age and gender based on randomized.

All data were entered to SPSS version 22 (SPSS crop., Chicago, IL, USA) and then analyzed. For reporting quantitative and qualitative data we used mean ± standard deviation and number or percent, respectively. For comparing quantitative and qualitative variables between groups independent t test, Chi Square and one-way ANOVA were used and also Pearson correlation was used to correlate between quantitative variables. A two-sided α level of 0.05 was used to assess statistical significance.

Results

In this study, 70 MS patients (13 males and 57 females with mean ages of 30.20 ± 1.42 years), 31 NMO patients (12 males and 19 females with mean ages of 29.64 ± 1.47 years) and 39
Multiple sclerosis

The means of serum level of IL-6 in the MS, NMO and healthy subject were $12.73 \pm 11.42, 7.30 \pm 4.94$ and $16.07 \pm 6.70$ pg/dl, respectively that this difference was significant between groups ($P=0.003$). The mean of serum level of IL-6 in the MS and NMO were significantly higher than healthy subjects ($P<0.001$ for both). Also the mean of serum level of IL-17 in the MS was significantly higher than NMO ($P=0.01$) (Figure 2).

Also there was no significant between males and females based on serum level of IL-6 ($P=0.19$) and IL-17 ($P=0.24$).

Pearson correlation showed there was a positive significant correlation between age and serum level of IL-6 ($r=0.23$, $P=0.01$) (Figure 3) but there was no significant correlation between age and serum level of IL-17 in all subjects ($r=-0.08$, $P=0.33$). Also there was a positive significant correlation between age and serum level of IL-17 in MS and NMO patients ($r=0.28$, $P=0.012$) (Figure 4).

Discussion

According our result, serum level of IL-6 in the patients with NMO was lower than MS and control. Also the serum level of IL-17 in patients with NMO or MS was higher than control and serum level of IL-17 in MS patients was higher than NMO cases. In addition, there was a positive significant correlation between age and serum level of IL-6.

Although NMO and MS were once supposed to be a single autoimmune disease, they are dif-

Table 1. Variables of study between groups

<table>
<thead>
<tr>
<th>Variables</th>
<th>Groups</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (m/f)</td>
<td>MS: 13/57</td>
<td>NMO: 12/19</td>
</tr>
<tr>
<td>Age (years) (mean ± SD)</td>
<td>30.20 ± 1.42</td>
<td>29.64 ± 1.47</td>
</tr>
<tr>
<td>IL-6 (pg/dl)</td>
<td>12.73 ± 11.42</td>
<td>7.30 ± 4.94</td>
</tr>
<tr>
<td>IL-17 (pg/dl)</td>
<td>11.54 ± 2.70</td>
<td>10.21 ± 2.76</td>
</tr>
</tbody>
</table>

Figure 1. Boxplot of serum level of IL-6 levels in MS, NMO and healthy subject based on gender. The mean of serum level of IL-6 in NMO patients was significantly lower than MS and healthy subjects (One-way ANOVA).
an increasing interest is in finding a biomarker to help early distinguish between MS and NMOSD.

One of the suggestive factor in genesis of both MS and NMOSD has been T and B cell interaction. it is considered that Th17 cells would have an important effect in the initial phase of MS [23].

Th17 cells have ability to disrupt the BBB and access the CNS and play a role in development of CNS autoimmunity. In addition, Th17 cells produce a large number of pro-inflammatory cytokines include mainly IL-17 [23].

IL-17, increases T cells activity. It can amplify endothelial inflammation by enforce endothelium to release pro-inflammatory mediators including IL-1, IL-6, TNFα and chemokines [24]. Finally, the role of IL-17 is causing local tissue inflammation by induction release of pro-inflammatory cytokines and neutrophils stimulating cytokine [25].

Based on IL-17 characteristics, it has been considering a strong association between IL-17 and the initial phase of MS disease [26].

Increased frequency of Th17 cells in the peripheral blood and cerebrospinal fluid (CSF) of some RRMS, especially during the acute episode has been reported [27].

In addition, there is some evidence implicating significant reduction in Th17 cell counts and IL-17 after IVMP pulse therapy in MS patients [28].

Along with these findings, Ghaffari et al has reported high level IL-17 concentrations in different entities in various respects, and must be treated with different therapies. For instance,
Multiple sclerosis

Although, one study found the level of IL-17 level was not higher in NMO than in MS [36]. Matsushita et al, compared NMO, RRMS, and PPMS and reported an increased expression of Th17 in NMOSD. In this study, of the total 73 patients, the CSF level of IL-17 and IL-6 were significantly higher in NMO patients than in RRMS at relapse [16].

In the study of Uzawa et al on 17 NMO patients and 21 MS patients, the CSF IL-6 levels were significantly higher in NMO patients in comparison to MS patients [16]. In contrast in the study of Li et al, memory Th17 and IL-17 level were much higher in both NMO or MS and were related to clinical feature which has been decreased following steroid therapy [19].

Conclusion

In the concluded of our result and other studies, IL-6 and IL-17 have important role in the neuroinflammatory diseases such as MS and NMO. There are limited evidences that reported there is a correlation between Th17 in NMO and MS diseases. In addition, most of studies that evaluated interleukins in MS and NMO patients, analyzed CSF and limited studies measured the serum level of these interleukins

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Reyhanehsadat Madanian, Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. E-mail: Rs.madanian@yahoo.com

References


newly diagnosed MS patients compare to healthy and treated MS patients [29].

On the other hand, high level of IL-17 were considered both in the CSF [18] and in the blood [22] of NMO patients.

Uzawa A, did not find an increase of IL-17 in CSF of NMO but find increase CSF level of IL-6 [30].

Different factors are involved for differentiation of B cells to producing immunoglobulin. IL-6 is one of B cell stimulating factor which differentiated B cell to plasma cell and leads to producing immunoglobulin [31, 32]. IL-6 is recognized as an important cytokine in inflammatory diseases of the central nervous system (CNS) is produced by different cells including activated monocytes, T cells, fibroblasts, endothelial cells, astrocytes and glial cells [31, 33].

IL-6 can increases the survival of plasmablasts that producing anti AQP4-IgG and result further tissue lesion [34].

Along with this characteristic, one study has showed higher proportion of IL-6 and IL-17 cell subsets in NMOSD patients than healthy controls and concluded that expansion of peripheral IL-6 and IL-17 T_{reg} cells may have a role in the severity of NMOSD [35].

Figure 4. Positive significant correlation between age and serum level of IL-17 in MS and NMO patients based on Pearson correlation.


Multiple sclerosis


